Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients

被引:56
作者
Paolisso, G
Tagliamonte, MR
Gambardella, A
Manzella, D
Gualdiero, P
Varricchio, G
Verza, M
Varricchio, M
机构
[1] Dept. Geriatric Med. and Metab. Dis., II University of Naples, Naples
[2] Dept. Geriatric Med. and Metab. Dis., Servizio di Astanteria Medica, I-80138 Napoli
关键词
losartan; insulin action; non-oxidative glucose metabolism;
D O I
10.1038/sj.jhh.1000434
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
We investigated the possible role of losartan on insulin-mediated glucose uptake, substrate oxidation and blood flow in insulin-resistant hypertensive patients. Sixteen newly diagnosed patients with mild-to-moderate hypertension were studied. The study design was a single-blind, randomised, placebo-controlled trial. After a 1 week run-in period, each patient was randomly assigned to placebo (n=7) and losartan (n=9). Both treatment periods lasted 4 weeks, At baseline, and at the end of the placebo and losartan treatment periods, euglycaemic hyperinsulinaemic glucose clamp and indirect calorimetry were performed. Before and along each glucose clamp, blood Row was also determined in the femoral artery by image-directed duplex ultrasonography combining B-mode imaging and pulse Doppler beams. Losartan vs placebo lowered systolic blood pressure by 163 +/- 3.5 and 147 +/- 4.1 mm Hg (P < 0.001), and diastolic blood pressure by 95 +/- 3.2 and 85 +/- 3.2 mmHg (P < 0.001). Losartan enhanced glucose metabolic clearance rate by 5.1 +/- 0.3 and 6.3 +/- 0.4 mg/kg x min (P < 0.05), and whole body glucose disposal (WBGD) by 29.2 +/- 0.5 and 38.1 +/- 0.4 mu mol/kg free fatty mass (FFM) x min (P < 0.01) but did not affect heart rate. Insulin-mediated change in blood flow was greater after losartan than placebo administration (111 +/- 4 vs 84 +/- 3%, P < 0.01). Per cent change in insulin-mediated stimulation of blood flow and WBGD were also correlated (r=0.76, P<0.01). Analysis of substrate oxidation revealed that losartan adminstration improved insulin action and non-oxidative glucose metabolism (NOGM) (30.8 +/- 2.2 vs 22.8 +/- 2.8 mu mol/kg FFM x min, P < 0.05), In conclusion losartan improves insulin-mediated glucose uptake through an increase in NOGM and blood flow in hypertensive patients.
引用
收藏
页码:307 / 312
页数:6
相关论文
共 28 条
[21]   RENIN-ANGIOTENSIN SYSTEM - BIOCHEMISTRY AND MECHANISMS OF ACTION [J].
PEACH, MJ .
PHYSIOLOGICAL REVIEWS, 1977, 57 (02) :313-370
[22]   A COMPARISON OF THE EFFECTS OF HYDROCHLOROTHIAZIDE AND CAPTOPRIL ON GLUCOSE AND LIPID-METABOLISM IN PATIENTS WITH HYPERTENSION [J].
POLLARE, T ;
LITHELL, H ;
BERNE, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (13) :868-873
[23]  
Reaven Gerald M., 1996, New England Journal of Medicine, V334, P374
[24]   ROLE OF INSULIN RESISTANCE IN HUMAN-DISEASE [J].
REAVEN, GM .
DIABETES, 1988, 37 (12) :1595-1607
[25]   IMPROVED INSULIN ACTION BY ACE INHIBITION IN TYPE-II DIABETICS [J].
RETT, K ;
LOTZ, N ;
WICKLMAYR, M ;
FINK, E ;
JAUCH, KW ;
GUNTHER, B ;
DIETZE, G .
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1988, 113 (07) :243-249
[26]  
SCHECTER M, 1995, J HUM HYPERTENS, V9, P663
[27]   INSULIN-MEDIATED SKELETAL-MUSCLE VASODILATION IS NITRIC-OXIDE DEPENDENT - A NOVEL ACTION OF INSULIN TO INCREASE NITRIC-OXIDE RELEASE [J].
STEINBERG, HO ;
BRECHTEL, G ;
JOHNSON, A ;
FINEBERG, N ;
BARON, AD .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (03) :1172-1179
[28]  
*WHO, 1985, DIAB MELL REP WHO ST, V727, P9